On March 31, 2022, the NIH begins clinical trials evaluating the second COVID-19 booster shots in adults with the Moderna mRNA vaccine, the study included new multiple-variant vaccines. The study is known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial.
Two days earlier on March 29, the CDC recommended the second booster for adults 50 years and older and the immune-compromised.
The NIH will study the Moderna and Pfizer mRNA vaccine, and claim that the “COVID-19 vaccine manufacturers can adjust prototype vaccines to target specific variants, a process similar to how manufacturers update seasonal influenza vaccines every year to target circulating strains…COVAIL trial will gather data on the immune responses induced by prototype vaccines and variant vaccine candidates—including bivalent vaccines, which target two SARS-CoV-2 variants—to inform booster shot recommendations.
Effectively any mRNA code can be readily generated on a computer and synthesised with these new “vaccine platforms“, but the protein-antigen that your body will be tricked into manufacturing could potentially be cytotoxic, as has been shown with the “spike protein”.
“We are looking beyond the Omicron variant to determine the best strategy to protect against future variants,”
said NIAID Director Anthony S. Fauci, M.D.
The challenge is, what will be the new variant?
They’ve thought about that too, the NIH has established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme to “address the public health threat caused by the increasing SARS-CoV-2 genomic diversity”, because new “variants jeopardizes the protective antiviral immunity induced after infection or vaccination”.